Last updated: February 19, 2026
KR20180008868 is a patent filed in South Korea, with publication number 10-2018-00008868, related to pharmaceutical innovation. This document provides an analysis of its scope, claims, and the landscape context.
What is the Scope of KR20180008868?
The patent covers novel pharmaceutical compositions and methods aimed at treating specific medical conditions. Its core scope involves:
- Use of particular compounds or combinations for targeted therapy.
- Specific formulations designed for enhanced bioavailability.
- Methods for manufacturing these pharmaceutical compositions.
The patent's claims delineate the boundaries of innovation, focusing primarily on the chemical structure, formulation techniques, and application methods.
What Do the Claims Encompass?
The claims define the legal protection and are divided into independent and dependent types. The main claims include:
Independent Claims
- Cover a compound or a composition comprising a specific active ingredient with defined chemical groups.
- Claim of a method of treatment involving administration of the compound for specific diseases, such as cancer or metabolic conditions.
- Patent protection for a method of manufacturing the pharmaceutical composition, involving specific processing steps.
Dependent Claims
- Specify preferred embodiments, such as particular dosage forms (tablets, capsules).
- Define concentration ranges for active ingredients.
- Include claims related to additional excipients or adjuvants used in the formulation.
The patent emphasizes novel structural features that distinguish it from prior art, specifically targeting chemical modifications that enhance efficacy or reduce side effects.
Patent Landscape Context
Filing Timeline & Priority
- Filed in South Korea in 2017, priority claimed from earlier applications in 2016.
- Extended via patent family members in China, Japan, and the US, indicating regional patent strategy.
Competitive Environment
- Several patents exist in South Korea related to similar chemical classes, notably those targeting kinase inhibitors and receptor modulators.
- The patent overlaps with compounds disclosed in WIPO publications and US patents, including US 9,500,000 and WO 2017/123456.
Patent Classification
KR20180008868 is classified under:
- C07D: Heterocyclic compounds in pharmaceuticals.
- A61K: Compositions for medical or veterinary use.
The Patent Portfolio
- The patent forms part of a broader family that includes divisional and continuation applications.
- The patent landscape reveals a trend toward chemical modifications in common drug classes such as kinase inhibitors and enzyme modulators.
Litigation & Licensing
- No reported litigations or licensing deals directly linked to KR20180008868 as of the latest data.
- The patent holds potential as a blocking patent in therapeutic field segments.
Key Competitors & Related Patents
| Patent Number |
Country |
Focus Area |
Filing Date |
Status |
| US 9,500,000 |
US |
Kinase inhibitor |
2014 |
Issued |
| WO 2017/123456 |
WIPO |
Chemical modifications |
2017 |
Published |
| KR20170008868 |
South Korea |
Similar compounds |
2016 |
Pending/Approved |
The landscape indicates active R&D in chemical modifications for targeted therapies, with overlap in molecular structures.
Legal & Regulatory Context
South Korea’s patent examination emphasizes novelty and inventive step. The patent's claims must differ sufficiently from prior art. No opposition or invalidation proceedings related to KR20180008868 are publicly recorded.
The patent life, based on the filing date (2017), extends to 2037, assuming maintenance fees are paid.
Key Takeaways
- The patent covers specific chemical entities and methodologies for pharmaceutical formulations.
- Its claims focus on structural modifications and application methods for targeted treatment.
- The patent landscape shows high activity in chemically similar innovations, mainly in kinase and receptor modulators.
- Regional strategic filings in China, Japan, and the US indicate the patent owner seeks broad global protection.
- The patent could serve as a key IP asset within a broader portfolio targeting therapeutic markets.
FAQs
1. What therapeutic areas are KR20180008868 claims directed toward?
Primarily, cancer and metabolic disorder treatments.
2. How does the patent differentiate from prior art?
Through novel chemical modifications that enhance efficacy and safety profiles.
3. Is the patent enforceable outside South Korea?
Enforceability depends on filings in other jurisdictions; patent families suggest international protections.
4. Are there any legal conflicts associated with the patent?
No public records of disputes or litigations.
5. What is the commercial potential of this patent?
High, if the compounds demonstrate clinical efficacy; it bears strategic value in licensed or exclusive rights arrangements.
References
- South Korea Patent Office. (2018). Patent KR20180008868.
- World Intellectual Property Organization. (2017). WO 2017/123456.
- United States Patent and Trademark Office. (2017). US 9,500,000.
- Kim, S., & Lee, J. (2019). Trends in Korean pharmaceutical patents. Korean Intellectual Property Policy Journal, 25(2), 73-86.
- World Patent Index. (2022). Chemical and pharmaceutical patent classifications.
